ArticleDiscover oncology2025
Inhibition of LINC01048 decreases cell proliferation and induces the apoptosis in gastric cancer.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
With advancements in the study of long non-coding RNAs (lncRNAs) as significant biomarkers and therapeutic targets in various human diseases, including cancer, neurodegenerative conditions, and genetic disorders, emerging evidence highlights their regulatory roles in the development of gastric cancer (GC). However, the mechanisms underlying these functions remain largely unknown. In this study, we investigate the role of the LINC01048 in tumorigenesis and cell proliferation in GC cell lines, such as HGC27 and MKN45. Analysis of publicly available databases and experimental validation revealed that LINC01048 expression is elevated in GC tissues and cell lines and is associated with poor prognosis. Knockdown of LINC01048 significantly suppressed cell proliferation and induced apoptosis in GC cells. Additionally, depletion of LINC01048 reduced the nuclear localization of β-catenin while increasing its cytoplasmic retention. Furthermore, treatment with SKL2001, a Wnt/β-catenin pathway activator, reversed the effects of LINC01048 knockdown on cell proliferation and apoptosis. In vivo experiments confirmed that LINC01048 depletion decreased tumor growth in GC xenograft models. Overall, these findings suggest that LINC01048 plays an oncogenic role in GC by promoting cell proliferation and modulating the Wnt/β-catenin pathway. Therefore, LINC01048 may serve as a potential therapeutic target for GC treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.